secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001564590-22-023045
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax appoints Keith A. Goldan as CFO; base salary $450k, option for 230k shares
--------------------------------------------------------------------------------

- Keith Goldan appointed CFO effective June 13, 2022; previously CFO at OptiNose.
- Employment terms: $450k base salary, 40% target bonus, option for 230k shares (4-yr vest), $50k RSU sign-on.
- Sharon Klahre named VP, Investor Relations and Communications, reporting to Goldan.
- Goldan brings ~30 years biopharma CFO experience; co. expects multiple pivotal readouts in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/0001564590-22-023045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022023045/sndx-8k_20220608.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer